Skip to main content

Table 3 Gender-specific subgroups: Overview of the absolute clinical outcome scores and biomarker values at baseline, week 2, week 6 and week 12 in the placebo and choline-stabilized orthosilicic acid (ch-OSA) group

From: A 12-week randomized, double-blind, placebo-controlled multicenter study of choline-stabilized orthosilicic acid in patients with symptomatic knee osteoarthritis

  Placebo (n = 79) ch-OSA (n = 87)
Male (n = 24) Female (n = 55) Male (n = 22) Female (n = 65)
Baseline (mean ± SD) Week 2 (mean ± SD) Week 6 (mean ± SD) Week 12 (mean ± SD) Baseline (mean ± SD) Week 2 (mean ± SD) Week 6 (mean ± SD) Week 12 (mean ± SD) Baseline (mean ± SD) Week 2 (mean ± SD) Week 6 (mean ± SD) Week 12 (mean ± SD) Baseline (mean ± SD) Week 2 (mean ± SD) Week 6 (mean ± SD) Week 12 (mean ± SD)
WOMAC total score (/100 mm) 42.0 ± 22.4 37.5a ± 26.2 34.1a ± 24.3 34.7 ± 30.7 43.6 ± 19.6 39.8 ± 19.0 32.1a, b ± 19.9 31.2 a ± 20.5 42.5 ± 20.9 36.1a ± 22.1 26.8a ± 22.8 24.2a ± 21.3 40.4 ± 19.0 37.7 ± 20.7 30.4a, b ± 21.2 31.1a ± 23.4
WOMAC pain score (/100 mm) 42.5 ± 22.7 35.1a ± 24.5 32.6a ± 24.0 33.0 ± 31.2 40.6 ± 19.4 37.2 ± 19.7 29.3a, b ± 19.8 28.2 a ± 20.1 41.3 ± 19.3 32.2a ± 20.0 24.3a ± 21.5 21.6a ± 19.6 37.1 ± 20.0 35.5 ± 21.9 28.8a, b ± 22.0 27.6a ± 22.9
WOMAC stiffness score (/100 mm) 43.8 ± 25.3 40.0 ± 27.3 33.5 ± 26.4 38.2 ± 29.6 45.9 ± 24.5 39.5a ± 23.2 32.4a, b ± 22.2 32.2 a ± 22.8 46.2 ± 21.8 37.2a ± 25.3 28.8a ± 23.8 24.1a ± 23.4 43.3 ± 24.1 39.4 ± 22.5 31.1a, b ± 22.6 32.0a ± 25.3
WOMAC function score (/100 mm) 41.7 ± 23.3 37.9 ± 27.3 34.6 ± 25.2 34.9 ± 31.0 45.9 ± 24.5 39.5 ± 23.2 32.4a, b ± 22.2 32.2 a ± 22.8 42.4 ± 22.2 27.1 ± 22.9 27.3a ± 23.5 25.0a ± 22.3 43.3 ± 24.1 39.4 ± 22.5 31.1a, b ± 22.6 32.0a ± 25.3
Subject Global Assessment (/100 mm) 51.1 ± 26.0 41.7 ± 22.4 33.3 a ± 23.4 33.8a ± 24.3 48.6 ± 19.9 37.9a ± 18.8 33.5a, b ± 19.7 32.0 a ± 22.2 51.5 ± 18.3 36.6a ± 20.9 24.6a, b ± 20.8 25.8 a ± 23.7 49.6 ± 18.3 42.7a ± 22.8 36.5a, b ± 24.9 34.2a ± 24.6
CTX-II/Creatinine (ng/mmol) 389.8 ± 178.0 - - 565.2a ± 267.8 425.6 ± 196.5 - - 508.1a ± 259.5 364.0 ± 144.7 - - 437.4a ± 171.8 454.3 ± 229.0 - - 568.3a ± 282.6
COMP (U/L) 11.1 ± 3.0 - - 13.0a ± 3.6 10.6 ± 2.7 - - 10.6 ± 3.2 10.9 ± 2.7 - - 10.6 ± 2.7 10.6 ± 2.9 - - 11.3a ± 2.8
Silicon (μg/L) 54.4 ± 28.1 - - 59.2 ± 36.0 49.5 ± 35.6    67.8 a ± 44.4 68.4 ± 38.0 - - 99.3a, c ± 42.7 57.0 ± 35.3 - - 121.3a, c ± 59.1
  1. asignificant difference from baseline within the group; b significant difference from week 2 within the group; c significant difference between groups (placebo versus ch-OSA); -: not applicable; Number of patients without outliers for CTX-II: placebo males (n = 23), placebo females (n = 43), ch-OSA males (n = 18), ch-OSA females (n = 50); Number of patients without outliers for COMP: placebo males (n = 22), placebo females (n = 52), ch-OSA males (n = 21), ch-OSA females (n = 59); Number of patients without outliers for Silicon: placebo males (n = 19), placebo females (n = 50), ch-OSA males (n = 19), ch-OSA females (n = 56)